Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Receivables - Net: 2012-2024

Historic Receivables - Net for Adma Biologics (ADMA) over the last 10 years, with Dec 2024 value amounting to $50.0 million.

  • Adma Biologics' Receivables - Net rose 174.58% to $137.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.7 million, marking a year-over-year increase of 174.58%. This contributed to the annual value of $50.0 million for FY2024, which is 82.34% up from last year.
  • Adma Biologics' Receivables - Net amounted to $50.0 million in FY2024, which was up 82.34% from $27.4 million recorded in FY2023.
  • Adma Biologics' 5-year Receivables - Net high stood at $50.0 million for FY2024, and its period low was $13.2 million during FY2020.
  • Moreover, its 3-year median value for Receivables - Net was $27.4 million (2023), whereas its average is $31.0 million.
  • Per our database at Business Quant, Adma Biologics' Receivables - Net surged by 115.88% in 2021 and then crashed by 45.74% in 2022.
  • Yearly analysis of 5 years shows Adma Biologics' Receivables - Net stood at $13.2 million in 2020, then surged by 115.88% to $28.6 million in 2021, then plummeted by 45.74% to $15.5 million in 2022, then skyrocketed by 76.85% to $27.4 million in 2023, then spiked by 82.34% to $50.0 million in 2024.